This is a positive step for GSK and hopefully other pharmaceutical companies will follow suit. Scientists and researchers external to GSK will be able to request data sets and examine trial data so that safety and effectiveness data can be independently assessed. Another positive step: GSK is posting the approved requests. These posts will include the name and affiliation of the lead researcher and information about the study being conducted.
Questions are still being raised, however, regarding whether the patient-level data made available by GSK is being accurately represented. Furthermore, as external researchers' requests are being reviewed by a GSK-appointed committee, questions have been raised about the interests of some of those included on the committee.
GSK Gives Update on Plans to Share Detailed Clinical Trial Data
Glaxo And Its Transparency Effort Finally Moves Forward
GSK Gives Update on Plans to Share Detailed Clinical Trial Data as Part of its Commitment to Transparency
GSK Clinical Study Request
GSK Boosts Trials Disclosures Sans Support from Pharma Peers
Glaxo Clashes With PhRMA Over Data Disclosure